February 15, 2024Open Access

Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Key Points

Key points are not available for this paper at this time.

Abstract

Although chimeric antigen receptor T therapy (CAR-T) cells are an established therapy for relapsed/refractory multiple myeloma (RRMM), there are no established models predicting outcome to identify patients who may benefit the most from CAR-T.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Nico Gagelmann

Universität Hamburg

Danai Dima

Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa

Maximilian Merz

Memorial Sloan Kettering Cancer Center

Journals

Journal of Clinical Oncology

Actions

Institutions

Cleveland Clinic

Hebrew University of Jerusalem

Universitat de Barcelona

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study